http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-368552-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f88f84fc279fe5d0b9b5ec3c88c2e2b2
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06Q20-047
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-32
filingDate 1969-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1971-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber ES-368552-A1
titleOfInvention A PROCEDURE FOR THE PREPARATION OF I - SUBSTITUTE - 4 - AROILPIPERIDINES.
abstract Novel compounds of the formula where R denotes acetyl, aryl, carbamoyl, NC 1-8 alkylcarbamoyloxy, carbamoyloxy, aryloxy, aroyl, ethoxy, 4-phenyl-1-piperazinylacetyl, NC 1-8 -alkylcarbamoyl, N,N-di(C 1-8 alkyl)carbamoyl, N-arylthiocarbamoyl, N-arylcarbamoyl, carbethoxy or 2,3-dihydroxypropyl R1 denotes H, F, Cl, Br, C 1-8 alkyl, C 1-8 alkoxy or CF 3 Y denotes -CH 2 - and n is 0, or 1-4, and acid addition salts thereof, may be obtained by the steps of (1) reacting nipecotic acid or isonipecotic acid with a lower acyl anhydride to form a 1- lower acyl nipecotic or isonipecotic acid, (2) reacting the latter with thionyl halide to form the corresponding acid halide, (3) reacting the product with an aryl compound in the presence of an aluminium trihalide to give a 1-lower acyl- 3- or 4-aroylpiperidine, (4) hydrolysing to form a 3- or 4-aroyl piperidine, (5) reacting the product with an arylalkyl halide, aryloxyalkyl halide, aroylalkyl halide, #-hydroxyalkyl halide, 4- phenyl-1-piperazinyl acetyl chloride, C 1-8 alkyl isocyanate, N,N-di(C 1-8 alkyl) carbamoyl halide, arylisothiocyanate, arylisocyanate, ethyl chloroformate, 2,3-dihydroxypropyl halide, nitrourea, sodium cyanate or 2-bromoethyl ethyl ether and where an #-hydroxyalkyl halide is used, (6) reacting the 1-(#-hydroxyalkyl)-4-aroylpiperidine with a C 1-8 alkyl isocyanate. 4-Aroylpiperidines may also be obtained by the steps: (1) dehydrating 1-acetyl-4-carbamoylpiperidine to 1-acetyl-4-cyanopiperidine, (2) reacting the product with an arylmagnesium halide to give a 1-acetyl-4-aroylpiperidine, (3) hydrolysing in an acidic medium to give a 4-aroyl-piperidine and reacting the latter as in (5) above. A further preparation of 4-aroyl-piperidines comprises reacting under cyclizing conditions using NaH a [gamma]-[N-(2-haloethyl)-N-substituted]-amino butyrophenone of Formula X Intermediates are prepared by reacting ethanolamine with 2-(p-fluorophenyl)-2-(3-chloropropyl)-1,3-dioxolane to yield 2-(p-fluorophenyl)- 2 - [3 - N - (2 - hydroxyethyl)aminopropyl]- 1,3- dioxolane, reacting this with 2-(o-methoxyphenoxy) ethyl bromide to give p-fluoro-[gamma][N-2- hydroxyethyl - N - 2 - (o - methoxyphenoxy)- ethyl]-aminobutyrophenone which is acidified with HCl and then reacted with SOCl 2 to form pfluoro - [gamma] - [N - (2 - chloroethyl) - N - (2 - omethoxyphenoxyethyl)amino]butyrophenone hydrochloride. Pharmaceutical compositions useful as tranquillizing agents comprise compounds of Formula I above and a pharmaceutically acceptable carrier, preferably in the form of tablets or soft gelatine capsules.
priorityDate 1968-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419573487
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413709382
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416149893
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419519841
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393641
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID700
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID430824729
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483691
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20088731
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2756286
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86676953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61141
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416134510
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4498
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416168317
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491804
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453278078
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393598
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62372
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420117036
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53627726
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396411
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1799099
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393768
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18474173
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID455824109
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419544143
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494814
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393349
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5359268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID517096
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2723778
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423390483
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3773

Total number of triples: 49.